Navigation Links
Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Date:5/24/2012

LEXINGTON, Ky. (May 24, 2012) David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

Cystic fibrosis is a life-threatening disease that causes mucus in the lungs to become too thick, which leads to severe pulmonary complications. This disease is one of the most common chronic lung diseases in children and young adults, affecting 30,000 children and adults in the United States and nearly 70,000 people worldwide, according to the Cystic Fibrosis Foundation.

Feola's research lab focuses on the regulatory function of macrophages, an immune cell type that kills invading pathogens and controls inflammation, in patients with chronic pulmonary inflammatory diseases. Cystic fibrosis causes progressive, life-threatening lung damage due in large part to repeated, dysregulated inflammatory responses to bacterial infection. Preliminary research in Feola's lab suggests that inducing specific types of macrophage activation could blunt this dysregulated inflammation. This research will lead to discovery of specific drug targets that could slow or halt this destructive cycle of inflammatory injury and pulmonary function decline in these patients.

"It is our hope that this research funding will provide us a greater understanding on how cystic fibrosis works, discover novel ways of treating the disease, and how we might be able to improve quality of life for these patients," said Feola, who also is a two-time graduate of the UK College of Pharmacy. Feola received his PharmD and PhD from the College.

Feola's grant is an investigator-initiated Research Project (R01) award, which is being funded by NIH's National Institute of Allergy and Infectious Diseases. R01 grant funding has become increasingly competitive due to the nation's current economic condition.

"The funding of this NIH grant is a testament to Dr. Feola's skill, expertise, tenacity and perseverance in pursing this support for his research program," said Linda Dwoskin, Associate Dean for Research for the UK College of Pharmacy. "I am extremely happy for him, his lab and the Pharmacy Practice and Science Department. I look forward to hearing about the great discoveries that result from Dr. Feola's research on cystic fibrosis."


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
2. University studies and career expectations of medical students
3. University of Minnesota startup to treat challenging bacterial infection
4. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. Neuropsychologist receives University of Houstons highest faculty honor
7. Louisiana Tech University professor earns NSF Early Career Development grant
8. Rice University student engineers automate limb lengthening for kids
9. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
10. University of Cincinnati researchers win $3.7M grant from US Department of Defense
11. Oxford University Press partners with the Physical Society of Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 26, 2016 ... value-based care operating models within the health care industry ... greater financial efficiency , Deloitte offers a suite ... key business issues impacting efficient cost optimization: labor resource ... , These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
Breaking Medicine Technology: